Alex Zhavoronkov

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. He is also the founder and Chief Longevity Officer (CLO, an unpaid advisory position) of Deep Longevity, Inc, a spin-off of Insilico Medicine, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and the life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).